Drug intelligence / Profile preview

ethinylestradiol + drospirenone

Development stage
Phase 4
Lead developer
Bayer
Modality
Small Molecules
Administration
Oral
01

Overview

Ethinylestradiol + drospirenone is a combined oral contraceptive (COC) medication consisting of a synthetic estrogen (ethinylestradiol) and a fourth-generation progestin (drospirenone). Drospirenone is a spironolactone analogue that possesses unique anti-mineralocorticoid and anti-androgenic properties, which help to counteract estrogen-related water retention and treat androgen-mediated symptoms such as acne and hirsutism. In the context of research conducted by Ege University, this combination is being specifically evaluated for its impact on psychological comorbidities, including anxiety and depression, in adolescent patients with polycystic ovary syndrome (PCOS). The treatment aims to regulate hormonal imbalances and menstrual cycles while the study monitors changes in mental health outcomes over a six-month period.

Brand names
SyedaOcellaZarah
Other names
ethinylestradiol/drospirenoneEE/DRSP
02

Targets

AR (Adrenergic receptors)ER (Estrogen receptor)MR (Mineralocorticoid receptor)PR (Progesterone receptor)

Beyond the preview

Go deeper on ethinylestradiol + drospirenone.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on ethinylestradiol + drospirenone.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call